Ranolazine vs. Trimetazidine in Chronic Angina Treatment

Comparative Efficacy

Ranolazine has more robust clinical evidence from contemporary, double-blind, placebo-controlled trials compared to trimetazidine, which has primarily been studied in historical, small, and often open-label trials 1, 2
Both medications are metabolic modulators but work through different mechanisms - ranolazine inhibits the late sodium current while trimetazidine shifts cardiac metabolism from fatty acid to glucose utilization 3

Ranolazine is strongly preferred over trimetazidine in patients with diabetes and chronic angina based on high-quality evidence 1, 4, 2
Ranolazine demonstrated favorable effects on glycated hemoglobin levels in a double-blind, placebo-controlled trial, significantly reducing HbA1c, fasting glucose, and 2-hour postprandial glucose levels 4

Both ranolazine and trimetazidine are contraindicated when glomerular filtration rate is <30 ml/min/1.73 m² 1, 2
Ranolazine undergoes extensive hepatic metabolism by cytochrome P450 and is primarily excreted by the kidney, with plasma levels increasing up to 50-60% in patients with moderate renal impairment 2

Ranolazine causes dose-dependent QT interval prolongation that requires monitoring, especially in patients with risk factors for arrhythmias 5

Trimetazidine is not recommended in patients with Parkinson's disease, parkinsonism, and other related movement disorders 3
Ranolazine should be used with caution in patients taking digoxin, as it may increase digoxin concentration by 40-60% through P-glycoprotein inhibition 5

For patients with diabetes and chronic angina: Choose ranolazine (preferred) due to proven benefits on glycemic control and angina symptoms 1, 2
For patients with renal impairment (GFR <30 ml/min): Avoid both medications 2
For patients with hepatic impairment: Avoid ranolazine and consider trimetazidine if no movement disorders 3, 5
For patients on digoxin: Use trimetazidine or monitor digoxin levels closely if ranolazine is necessary 5
For patients with movement disorders: Avoid trimetazidine and consider ranolazine 3